Poly(ADP-ribose) polymerase inhibitor olaparib hampers placental growth factor-driven activation 
of myelomonocytic cells

Lacal,Pedro  Miguel; Atzori,Maria  Grazia; Ruffini,Federica; Tentori,Lucio; Graziani,Grazia

doi:10.3892/or.2018.6291

Poly(ADP-ribose) polymerase inhibitor olaparib hampers placental growth factor-driven activation of myelomonocytic cells

Authors:
- Pedro Miguel Lacal
- Maria Grazia Atzori
- Federica Ruffini
- Lucio Tentori
- Grazia Graziani
View Affiliations

Affiliations: Laboratory of Molecular Oncology, ‘Istituto Dermopatico dell'Immacolata’‑IRCCS, I‑00167 Rome, Italy, Department of Systems Medicine, University of Rome ‘Tor Vergata’, I‑00133 Rome, Italy
Published online on: March 5, 2018 https://doi.org/10.3892/or.2018.6291
Pages: 2261-2269

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The vascular endothelial growth factor receptor-1 (VEGFR-1) is a tyrosine kinase receptor activated by the angiogenic factors VEGF‑A and placental growth factor (PlGF). While VEGF‑A binds to both VEGFR‑1 and VEGFR‑2, PlGF interacts exclusively with VEGFR‑1 triggering a signaling pathway involved in: i) tumor‑associated angiogenesis; ii) chemotaxis and invasion of the extracellular matrix (ECM) by cancer cells; and iii) mobilization of bone marrow‑derived myeloid cells that generate tumor‑associated macrophages. By using a novel anti‑VEGFR‑1 monoclonal antibody (D16F7 mAb), which hampers receptor activation without avoiding ligand binding, we recently demonstrated that VEGFR‑1 blockade reduced myeloid progenitor mobilization and monocyte/macrophage cell infiltration of tumor grafts in vivo. Since poly(ADP‑ribose) polymerase (PARP)‑1 exerts a pro‑inflammatory role favoring monocyte activation, in the present study we investigated whether the PARP inhibitor (PARPi) olaparib hampers PlGF‑induced activation of human myelomonocytic cells. HL‑60 cells induced to differentiate towards the monocytic/macrophage lineage were tested and the results were confirmed in freshly isolated monocytes obtained from healthy donors. Cells were treated with olaparib, at clinically achievable concentrations, before exposure to PlGF and were analyzed for migration and ECM invasion in response to PlGF. Olaparib effects were compared to those obtained with D16F7 mAb used as single agent or in combination with the PARPi. The results indicate that differentiated HL‑60 cells and monocytes expressed VEGFR‑1 and migrated in response to PlGF. Moreover, olaparib and D16F7 inhibited PlGF‑induced chemotaxis and ECM invasion in a dose‑dependent manner and with similar efficacy. However, in combination studies the PARPi and D16F7 did not exert synergistic effects. Olaparib also hampered PlGF‑induced monocyte adhesion to fibronectin, while it did not affect NF‑κB activation in response to the angiogenic factor. These data suggest that olaparib likely interferes with the same pathway affected by the anti‑VEGFR‑1 mAb and that inhibition of PlGF-induced monocyte activation may contribute to PARPi antitumor activity.

View Figures

View References

1	Clauss M, Weich H, Breier G, Knies U, Röckl W, Waltenberger J and Risau W: The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem. 271:17629–17634. 1996. View Article : Google Scholar : PubMed/NCBI
2	Kim KJ, Cho CS and Kim WU: Role of placenta growth factor in cancer and inflammation. Exp Mol Med. 44:10–19. 2012. View Article : Google Scholar : PubMed/NCBI
3	Ding Y, Huang Y, Song N, Gao X, Yuan S, Wang X, Cai H, Fu Y and Luo Y: NFAT1 mediates placental growth factor-induced myelomonocytic cell recruitment via the induction of TNF-alpha. J Immunol. 184:2593–2601. 2010. View Article : Google Scholar : PubMed/NCBI
4	Kerber M, Reiss Y, Wickersheim A, Jugold M, Kiessling F, Heil M, Tchaikovski V, Waltenberger J, Shibuya M, Plate KH and Machein MR: Flt-1 signaling in macrophages promotes glioma growth in vivo. Cancer Res. 68:7342–7351. 2008. View Article : Google Scholar : PubMed/NCBI
5	Laurent J, Hull EF, Touvrey C, Kuonen F, Lan Q, Lorusso G, Doucey MA, Ciarloni L, Imaizumi N, Alghisi GC, et al: Proangiogenic factor PlGF programs CD11b⁺ myelomonocytes in breast cancer during differentiation of their hematopoietic progenitors. Cancer Res. 71:3781–3791. 2011. View Article : Google Scholar : PubMed/NCBI
6	Czepluch FS, Olieslagers S, van Hulten R, Vöö SA and Waltenberger J: VEGF-A-induced chemotaxis of CD16+ monocytes is decreased secondary to lower VEGFR-1 expression. Atherosclerosis. 215:331–338. 2011. View Article : Google Scholar : PubMed/NCBI
7	Lin YL, Liang YC and Chiang BL: Placental growth factor down-regulates type 1 T helper immune response by modulating the function of dendritic cells. J Leukoc Biol. 82:1473–1480. 2007. View Article : Google Scholar : PubMed/NCBI
8	Zhou X and Qi Y: Larynx carcinoma regulates tumor-associated macrophages through PLGF signaling. Sci Rep. 5:100712015. View Article : Google Scholar : PubMed/NCBI
9	Selvaraj SK, Giri RK, Perelman N, Johnson C, Malik P and Kalra VK: Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood. 102:1515–1524. 2003. View Article : Google Scholar : PubMed/NCBI
10	Pagani E, Ruffini F, Cappellini Antonini GC, Scoppola A, Fortes C, Marchetti P, Graziani G, D'Atri S and Lacal PM: Placenta growth factor and neuropilin-1 collaborate in promoting melanoma aggressiveness. Int J Oncol. 48:1581–1589. 2016. View Article : Google Scholar : PubMed/NCBI
11	Graziani G, Ruffini F, Tentori L, Scimeca M, Dorio AS, Atzori MG, Failla CM, Morea V, Bonanno E, D'Atri S and Lacal PM: Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding. Oncotarget. 7:72868–72885. 2016. View Article : Google Scholar : PubMed/NCBI
12	Atzori MG, Tentori L, Ruffini F, Ceci C, Lisi L, Bonanno E, Scimeca M, Eskilsson E, Daubon T, Miletic H, et al: The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells. J Exp Clin Cancer Res. 36:1062017. View Article : Google Scholar : PubMed/NCBI
13	Atzori MG, Tentori L, Ruffini F, Ceci C, Bonanno E, Scimeca M, Lacal PM and Graziani G: The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits glioma growth and angiogenesis in vivo. J Pharmacol Exp Ther. 364:77–86. 2018. View Article : Google Scholar : PubMed/NCBI
14	Berger NA, Besson VC, Boulares AH, Bürkle A, Chiarugi A, Clark RS, Curtin NJ, Cuzzocrea S, Dawson TM, Dawson VL, et al: Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases. Br J Pharmacol. 175:192–222. 2018. View Article : Google Scholar : PubMed/NCBI
15	Martin-Hernandez K, Rodriguez-Vargas JM, Schreiber V and Dantzer F: Expanding functions of ADP-ribosylation in the maintenance of genome integrity. Semin Cell Dev Biol. 63:92–101. 2017. View Article : Google Scholar : PubMed/NCBI
16	Bai P and Virág L: Role of poly(ADP-ribose) polymerases in the regulation of inflammatory processes. FEBS Lett. 586:3771–3777. 2012. View Article : Google Scholar : PubMed/NCBI
17	Rom S, Zuluaga-Ramirez V, Reichenbach NL, Dykstra H, Gajghate S, Pacher P and Persidsky Y: PARP inhibition in leukocytes diminishes inflammation via effects on integrins/cytoskeleton and protects the blood-brain barrier. J Neuroinflammation. 13:2542016. View Article : Google Scholar : PubMed/NCBI
18	Shah GM, Robu M, Purohit NK, Rajawat J, Tentori L and Graziani G: PARP inhibitors in cancer therapy: Magic bullets but moving targets. Front Oncol. 3:2792013. View Article : Google Scholar : PubMed/NCBI
19	Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, et al: Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 18:1274–1284. 2017. View Article : Google Scholar : PubMed/NCBI
20	Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, et al: Olaparib for metastatic breast cancer in patients with a Germline BRCA mutation. N Engl J Med. 377:523–533. 2017. View Article : Google Scholar : PubMed/NCBI
21	Faraoni I, Compagnone M, Lavorgna S, Angelini DF, Cencioni MT, Piras E, Panetta P, Ottone T, Dolci S, Venditti A, et al: BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib. Biochim Biophys Acta. 1852:462–472. 2015. View Article : Google Scholar : PubMed/NCBI
22	Ruffini F, Failla CM, Orecchia A, Bani MR, Dorio AS, Fortes C, Zambruno G, Graziani G, Giavazzi R, D'Atri S, et al: Expression of the soluble vascular endothelial growth factor receptor-1 in cutaneous melanoma: Role in tumour progression. Br J Dermatol. 164:1061–1070. 2011. View Article : Google Scholar : PubMed/NCBI
23	Lacal PM, Morea V, Ruffini F, Orecchia A, Dorio AS, Failla CM, Soro S, Tentori L, Zambruno G, Graziani G, et al: Inhibition of endothelial cell migration and angiogenesis by a vascular endothelial growth factor receptor-1 derived peptide. Eur J Cancer. 44:1914–1921. 2008. View Article : Google Scholar : PubMed/NCBI
24	Levati L, Ruffini F, Muzi A, Umezawa K, Graziani G, D'Atri S and Lacal PM: Placenta growth factor induces melanoma resistance to temozolomide through a mechanism that involves the activation of the transcription factor NF-κB. Int J Oncol. 38:241–247. 2011.PubMed/NCBI
25	White ES, Livant DL, Markwart S and Arenberg DA: Monocyte-fibronectin interactions, via alpha(5)beta(1) integrin, induce expression of CXC chemokine-dependent angiogenic activity. J Immunol. 167:5362–5366. 2001. View Article : Google Scholar : PubMed/NCBI
26	Dewerchin M and Carmeliet P: Placental growth factor in cancer. Expert Opin Ther Targets. 18:1339–1354. 2014. View Article : Google Scholar : PubMed/NCBI
27	Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT and Sorensen AG: Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol. 6:327–338. 2009. View Article : Google Scholar : PubMed/NCBI
28	Bagley RG, Ren Y, Weber W, Yao M, Kurtzberg L, Pinckney J, Bangari D, Nguyen C, Brondyk W, Kaplan J and Teicher BA: Placental growth factor upregulation is a host response to antiangiogenic therapy. Clin Cancer Res. 17:976–988. 2011. View Article : Google Scholar : PubMed/NCBI
29	Carmeliet P and Jain RK: Molecular mechanisms and clinical applications of angiogenesis. Nature. 473:298–307. 2011. View Article : Google Scholar : PubMed/NCBI
30	Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Koch M, De Mol M, et al: Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell. 131:463–475. 2007. View Article : Google Scholar : PubMed/NCBI
31	Coenegrachts L, Maes C, Torrekens S, Van Looveren R, Mazzone M, Guise TA, Bouillon R, Stassen JM, Carmeliet P and Carmeliet G: Anti-placental growth factor reduces bone metastasis by blocking tumor cell engraftment and osteoclast differentiation. Cancer Res. 70:6537–6547. 2010. View Article : Google Scholar : PubMed/NCBI
32	Wei SC, Tsao PN, Weng MT, Cao Z and Wong JM: Flt-1 in colorectal cancer cells is required for the tumor invasive effect of placental growth factor through a p38-MMP9 pathway. J Biomed Sci. 20:392013. View Article : Google Scholar : PubMed/NCBI
33	Yao J, Wu X, Zhuang G, Kasman IM, Vogt T, Phan V, Shibuya M, Ferrara N and Bais C: Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. Proc Natl Acad Sci USA. 108:11590–11595. 2011. View Article : Google Scholar : PubMed/NCBI
34	Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, Coulon C, Squadrito ML, Segura I, Li X, Knevels E, et al: HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell. 19:31–44. 2011. View Article : Google Scholar : PubMed/NCBI
35	Galdiero MR, Garlanda C, Jaillon S, Marone G and Mantovani A: Tumor associated macrophages and neutrophils in tumor progression. J Cell Physiol. 228:1404–1412. 2013. View Article : Google Scholar : PubMed/NCBI
36	Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, et al: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 361:123–134. 2009. View Article : Google Scholar : PubMed/NCBI
37	Roth J, Peer CJ, Mannargudi B, Swaisland H, Lee JM, Kohn EC and Figg WD: A sensitive and robust ultra HPLC assay with tandem mass spectrometric detection for the quantitation of the PARP inhibitor olaparib (AZD2281) in Human plasma for pharmacokinetic application. Chromatography. 1:82–95. 2014. View Article : Google Scholar
38	Plummer R, Swaisland H, Leunen K, van Herpen CM, Jerusalem G, De Grève J, Lolkema MP, Soetekouw P, Mau-Sørensen M, Nielsen D, et al: Olaparib tablet formulation: Effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours. Cancer Chemother Pharmacol. 76:723–729. 2015. View Article : Google Scholar : PubMed/NCBI
39	Xia Y, Shen S and Verma IM: NF-κB, an active player in human cancers. Cancer Immunol Res. 2:823–830. 2014. View Article : Google Scholar : PubMed/NCBI
40	Askari JA, Buckley PA, Mould AP and Humphries MJ: Linking integrin conformation to function. J Cell Sci. 122:165–170. 2009. View Article : Google Scholar : PubMed/NCBI
41	Ferreira AM, Isaacs H, Hayflick JS, Rogers KA and Sandig M: The p110delta isoform of PI3K differentially regulates beta1 and beta2 integrin-mediated monocyte adhesion and spreading and modulates diapedesis. Microcirculation. 13:439–456. 2006. View Article : Google Scholar : PubMed/NCBI
42	Tchaikovski V, Fellbrich G and Waltenberger J: The molecular basis of VEGFR-1 signal transduction pathways in primary human monocytes. Arterioscler Thromb Vasc Biol. 28:322–328. 2008. View Article : Google Scholar : PubMed/NCBI